akerotx

As we welcome a new year, we’re reminded of the importance of progress, resilience, and our ongoing commitment to advancing research and therapies to transform the lives of people living with serious metabolic diseases. Wishing you a healthy, hopeful, and inspiring start to 2026!

From our team to yours, Happy Holidays! We’re proud of what we accomplished together this year and grateful for the people who make it all possible. Wishing you all a joyous and restful holiday season.

As 2025 comes to a close, we’re grateful for the dedication of our team, partners, investigators, patients, and advocates who propelled #TeamAkero forward. Looking ahead to 2026, we are energized by the momentum behind our science, our team, and our commitment to patients.

The acquisition of Akero by @novonordisk has been completed, marking an exciting milestone for the continued advancement #EFX—which offers class-leading potential for the treatment of #MASH and compliments Novo Nordisk’s metabolic disease portfolio. novonordisk.com/content/nncorp…

🦃 Wishing you a healthy and happy #Thanksgiving from all of us at #TeamAkero!

A huge shoutout to our team for an inspiring series of offsite gatherings over the past few weeks! The creativity and commitment across our organization remind us how much we can accomplish when we’re aligned and inspired by a shared purpose. #TeamAkero #Biotech #MASH

This year’s @AASLD #TLM25 emphasized the novel research in MASH treatment. We were proud to share the latest efruxifermin data from SYMMETRY & HARMONY in 2 oral and 2 poster presentations. Our thanks and appreciation to the experts who are driving innovation in the field of MASH.

Join us at #TLM2025 as we share new data reinforcing the antifibrotic activity of efruxifermin observed in the SYMMETRY and HARMONY trials across 4 presentations! Learn more about our presentations: ir.akerotx.com/news-releases/… @AASLDtweets #EFX #MASH

This past weekend our team had the privilege of participating in the Liver Life Walk in San Francisco. Events like these remind us why we do what we do. A huge thank you to the @liverUSA for hosting and bringing the community together to drive progress for patients and families.

A big thank you to our Clinical Development Team for an energizing offsite! This offsite gave us the chance to connect, reflect, and align around our shared mission to advance treatment options for MASH and MASLD. #Biotech #MASH #MASLD #TeamAkero

October is #NationalLiverAwarenessMonth. Metabolic liver diseases like #MASH and #MASLD affect millions, often silently. As a company focused on liver health, we believe education is key. Learn more via @liverUSA: liverfoundation.org/resource-cente…

See you in Washington, DC forthe @AASLDtweets The Liver Meeting 2025! You won’t want to miss our 2 oral presentations and poster highlighting data from our 96-week Phase 2b SYMMETRY study of #EFX. ir.akerotx.com/news-releases/… #TLM2025 #AASLD2025 #MASH

Join us tomorrow at the @HansonWade 9th Annual #MASH Drug Development Summit as our Director of Translational Biology and Pharmacology, Erik Tillman, PhD, shares a talk highlighting #EFX’s anti-fibrotic effects corroborated by noninvasive biomarkers and serial-biopsies.

Aging brings new reasons to act with intention. Metabolic diseases like MASLD and MASH can progress silently, but early action makes all the difference. At Akero, we’re committed to building a future where people can age with strength and clarity. #HealthyAgingMonth

Join us on Monday, September 8th at 10:45 AM ET as we present at the @MorganStanley 23rd Annual Healthcare Conference. A live stream link will be available on our website for those looking to tune in virtually. Read more at: ir.akerotx.com/news-releases/…

Today, Akero announced the publication of 96-week results from the Phase 2b HARMONY trial in @TheLancet, supporting #EFX’s potential to reduce risk of fibrosis progression in pre-cirrhotic (F2-F3) MASH. Learn more: thelancet.com/journals/lance…

Today, $AKRO reported Q2 2025 financial results and provided business updates. Read more at: ir.akerotx.com/news-releases/…

Namaste from Chandigarh, India for the Annual @INASL_Liver scientific meeting! Join us Saturday, August 9th at 14:30 IST for an oral presentation highlighting how #EFX improved fibrosis in patients with F2/F3 #fibrosis or compensated #cirrhosis due to #MASH. #INASL2025

@JHepatology article from CSO, Tim Rolph, highlights research revealing how FGF21 clears liver fat & impacts cell metabolism. The result: new insight into the therapeutic mechanisms of investigational #FGF21 analogues, like #EFX, for the treatment of #MASH authors.elsevier.com/a/1lWJDcOnAYUaz

We recently wrapped up productive investigator meetings in Chile & Argentina as we expand global trial access for #MASH & #MASLD. Grateful to our LATAM teams for their hospitality & dedication to advancing diverse, inclusive liver disease research. #ClinicalTrials